Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Home > Markets > IPO > IPO News
Select Items

IPO News

12-Nov-2020 (09:30) Gland Pharma IPO subscribed 2.06 times

The initial public offer (IPO) of Gland Pharma received bids for 6.21 crore shares on Wednesday, 11 November 2020, as against 3.02 crore shares on offer. The issue was subscribed 2.06 times.

The qualified institutional buyers (QIBs) category was subscribed 6.40 times. The non-institutional investors category was subscribed 51% and the retail individual investors category was subscribed 24%.

The issue opened for bidding on Monday, 9 November 2020 and it closed Wednesday, 11 November 2020. The price band for the IPO was set at Rs 1490-1500 per share.

The IPO consisted of fresh issue of shares amounting to Rs 1250 crore and an offer of sale of 3,48,63,635 shares by the selling shareholders.

Ahead of the IPO, the Hyderabad-based generic injectables-focused company allotted 1,29,59,089 shares to 70 anchor investors at Rs 1,500 per share aggregating to Rs 1,943.86 crore.

Overseas investors included SmallCap World Fund INC, Government of Singapore, The Nomura Trust And Banking Co and Goldman Sachs.

Out of the total 1,29,59,089 shares allotted to anchor investors, the company allocated 43,19,700 shares (or 33.33% of the total anchor allotment portion) to 18 domestic mutual funds through a total of 77 schemes.

The proceeds of the offer for sale shall be received by the selling shareholders. The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables. The company is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Powered by Capital Market - Live News

11-Nov-2020 (17:25) Gland Pharma IPO subscribed over two times

The initial public offer (IPO) of Gland Pharma received bids for 6.21 crore shares on Wednesday, 11 November 2020, as against 3.02 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:30 IST. The issue was subscribed 2.06 times.

The issue opened for bidding on Monday, 9 November 2020 and it will close today, 11 November 2020. The price band for the IPO was set at Rs 1490-1500 per share.

The IPO consisted of fresh issue of shares amounting to Rs 1250 crore and an offer of sale of 3,48,63,635 shares by the selling shareholders.

Ahead of the IPO, the Hyderabad-based generic injectables-focused company allotted 1,29,59,089 shares to 70 anchor investors at Rs 1,500 per share aggregating to Rs 1,943.86 crore.

Overseas investors included SmallCap World Fund INC, Government of Singapore, The Nomura Trust And Banking Co and Goldman Sachs.

Out of the total 1,29,59,089 shares allotted to anchor investors, the company allocated 43,19,700 shares (or 33.33% of the total anchor allotment portion) to 18 domestic mutual funds through a total of 77 schemes.

The proceeds of the offer for sale shall be received by the selling shareholders. The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables. The company is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Powered by Capital Market - Live News

10-Nov-2020 (17:34) Gland Pharma IPO subscribed 22%

The initial public offer (IPO) of Gland Pharma received bids for 65.03 lakh shares on Tuesday, 10 November 2020, as against 3.02 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:00 IST. The issue was subscribed 0.22 times.

The issue opened for bidding on Monday, 9 November 2020 and it will close on Wednesday, 11 November 2020. The price band for the IPO is set at Rs 1490-1500 per share.

The IPO consists of fresh issue of shares amounting to Rs 1250 crore and an offer of sale of 3,48,63,635 shares by the selling shareholders.

Ahead of the IPO, the Hyderabad-based generic injectables-focused company allotted 1,29,59,089 shares to 70 anchor investors at Rs 1,500 per share aggregating to Rs 1,943.86 crore.

Overseas investors included SmallCap World Fund INC, Government of Singapore, The Nomura Trust And Banking Co and Goldman Sachs.

Out of the total 1,29,59,089 shares allotted to anchor investors, the company allocated 43,19,700 shares (or 33.33% of the total anchor allotment portion) to 18 domestic mutual funds through a total of 77 schemes.

The proceeds of the offer for sale shall be received by the selling shareholders. The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables. The company is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Powered by Capital Market - Live News

09-Nov-2020 (17:31) Gland Pharma IPO subscribed 4%

The initial public offer (IPO) of Gland Pharma received bids for 12.69 lakh shares on Monday, 9 November 2020, as against 3.02 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:00 IST. The issue was subscribed 0.04 times.

The issue opened for bidding today, 9 November 2020 and it will close on Wednesday, 11 November 2020. The price band for the IPO is set at Rs 1490-1500 per share.

The IPO consists of fresh issue of shares amounting to Rs 1250 crore and an offer of sale of 3,48,63,635 shares by the selling shareholders.

Ahead of the IPO, the Hyderabad-based generic injectables-focused company allotted 1,29,59,089 shares to 70 anchor investors at Rs 1,500 per share aggregating to Rs 1,943.86 crore.

Overseas investors included SmallCap World Fund INC, Government of Singapore, The Nomura Trust And Banking Co and Goldman Sachs.

Out of the total 1,29,59,089 shares allotted to anchor investors, the company allocated 43,19,700 shares (or 33.33% of the total anchor allotment portion) to 18 domestic mutual funds through a total of 77 schemes.

The proceeds of the offer for sale shall be received by the selling shareholders. The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables. The company is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Powered by Capital Market - Live News

07-Nov-2020 (17:29) Gland Pharma raises Rs 1,944 cr from anchor investors ahead of IPO

Overseas investors included SmallCap World Fund INC, Government of Singapore, The Nomura Trust And Banking Co and Goldman Sachs.

Out of the total 1,29,59,089 shares allotted to anchor investors, the company allocated 43,19,700 shares (or 33.33% of the total anchor allotment portion) to 18 domestic mutual funds through a total of 77 schemes.

Axis Mutual Fund, SBI Mutual Fund, Aditya Birla Sun Life Mutual Fund, ICICI Prudential Mutual Fund, Nippon India Mutual Fund, Franklin Templeton Mutual Fund and Kotak Mutual Fund are some of the domestic mutual fund companies that were allotted shares in the anchor allotment process.

The initial public offer (IPO) of Gland Pharma will open for bidding on Monday, 9 November 2020 and it will close on Wednesday, 11 November 2020. The price band for the IPO is set at Rs 1490-1500 per share.

The IPO consists of fresh issue of shares amounting to Rs 1250 crore and an offer of sale of 3,48,63,635 shares by the selling shareholders.

The proceeds of the offer for sale shall be received by the selling shareholders. The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables. The company is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Powered by Capital Market - Live News

23-Oct-2020 (12:33) Equitas Small Finance Bank IPO ends with decent subscription

The initial public offer (IPO) of Equitas Small Finance Bank received bids for 22.57 crore shares as against 11.58 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:00 IST. The issue was subscribed 1.95 times.

The qualified institutional buyers (QIBs) category was subscribed 3.91 times. The retail individual investors (RIIs) category was subscribed 2.08 times. The non-institutional investors category was subscribed 0.22 times.

The issue opened for bidding on 20 October 2020 and closed on 22 October 2020. The price band for the IPO was set at Rs 32-33 per share.

The IPO consisted of fresh issue of shares amounting to Rs 280 crore and an offer of sale comprised of 7.20 crore shares by the bank's promoter, Equitas Holdings (including anchor portion of 4.23 crore equity shares).

Ahead of the IPO, Equitas Small Finance Bank raised Rs 139.68 crore from anchor investors on 19 October 2020. It has finalised allotment of 4,23,27,271 equity shares to anchor investors at upper price band of Rs 33 per equity share.

The bank proposes to utilize the net proceeds from the offer towards augmenting bank's Tier I capital base to meet bank's future capital requirements such as organic growth and expansion and to comply with the regulatory requirements for enhanced capital base, as may be prescribed in the future.

The listing of the bank is also in line with terms of the RBI in-principle approval, RBI final approval and SFB licensing guidelines, requiring the bank to list its equity shares on the stock exchanges within three years from the date of commencement of business by the bank.

The small finance bank recorded net profit of Rs 57.67 crore and total income of Rs 750.96 crore in the quarter ended on 30 June 2020.

Equitas Small Finance Bank is the largest small finance bank in India in terms of number of banking outlets and the second largest SFB in India in terms of assets under management and total deposits in FY2019. The bank has successfully diversified its loan portfolio and significantly reduced its dependence on microfinance business as compared to other microfinance companies that have converted to SFBs.

The bank offers a range of banking products and services to customers with a focus on serving the financially unserved and underserved customer segments in India. Its strength lies in promoting financial inclusion within these segments.

Powered by Capital Market - Live News

22-Oct-2020 (17:07) Equitas Small Finance Bank IPO subscribed 1.95 times

The initial public offer (IPO) of Equitas Small Finance Bank received bids for 22.57 crore shares on Thursday, 22 October 2020, as against 11.58 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:00 IST. The issue was subscribed 1.95 times.

The issue opened for bidding on 20 October 2020 and it will close today, 22 October 2020. The price band for the IPO was set at Rs 32-33 per share.

The IPO consisted of fresh issue of shares amounting to Rs 280 crore and an offer of sale comprised of 7.20 crore shares by the bank's promoter, Equitas Holdings (including anchor portion of 4.23 crore equity shares).

Ahead of the IPO, Equitas Small Finance Bank raised Rs 139.68 crore from anchor investors on 19 October 2020. It has finalised allotment of 4,23,27,271 equity shares to anchor investors at upper price band of Rs 33 per equity share.

The bank proposes to utilize the net proceeds from the offer towards augmenting bank's Tier I capital base to meet bank's future capital requirements such as organic growth and expansion and to comply with the regulatory requirements for enhanced capital base, as may be prescribed in the future.

The listing of the bank is also in line with terms of the RBI in-principle approval, RBI final approval and SFB licensing guidelines, requiring the bank to list its equity shares on the stock exchanges within three years from the date of commencement of business by the bank.

The small finance bank recorded net profit of Rs 57.67 crore and total income of Rs 750.96 crore in the quarter ended on 30 June 2020.

Equitas Small Finance Bank is the largest small finance bank in India in terms of number of banking outlets and the second largest SFB in India in terms of assets under management and total deposits in FY2019. The bank has successfully diversified its loan portfolio and significantly reduced its dependence on microfinance business as compared to other microfinance companies that have converted to SFBs.

The bank offers a range of banking products and services to customers with a focus on serving the financially unserved and underserved customer segments in India. Its strength lies in promoting financial inclusion within these segments.

Powered by Capital Market - Live News

21-Oct-2020 (17:16) Equitas Small Finance Bank IPO subscribed 67%

The initial public offer (IPO) of Equitas Small Finance Bank received bids for 7.80 crore shares on Wednesday, 21 October 2020, as against 11.58 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:00 IST. The issue was subscribed 0.67 times.

The issue opened for bidding on Tuesday, 20 October 2020 and it will close on Thursday, 22 October 2020. The price band for the IPO is set at Rs 32-33 per share.

The IPO consists of fresh issue of shares amounting to Rs 280 crore and an offer of sale comprises of 7.20 crore shares by the bank's promoter, Equitas Holdings (including anchor portion of 4.23 crore equity shares).

Ahead of the IPO, Equitas Small Finance Bank raised Rs 139.68 crore from anchor investors on 19 October 2020. It has finalised allotment of 4,23,27,271 equity shares to anchor investors at upper price band of Rs 33 per equity share.

The bank proposes to utilize the net proceeds from the offer towards augmenting bank's Tier I capital base to meet bank's future capital requirements such as organic growth and expansion and to comply with the regulatory requirements for enhanced capital base, as may be prescribed in the future.

The listing of the bank is also in line with terms of the RBI in-principle approval, RBI final approval and SFB licensing guidelines, requiring the bank to list its equity shares on the stock exchanges within three years from the date of commencement of business by the bank.

Equitas Small Finance Bank recorded net profit of Rs 57.67 crore and total income of Rs 750.96 crore in the quarter ended on 30 June 2020.

Equitas Small Finance Bank is the largest small finance bank in India in terms of number of banking outlets and the second largest SFB in India in terms of assets under management and total deposits in FY2019. The bank has successfully diversified its loan portfolio and significantly reduced its dependence on microfinance business as compared to other microfinance companies that have converted to SFBs.

The bank offers a range of banking products and services to customers with a focus on serving the financially unserved and underserved customer segments in India. Its strength lies in promoting financial inclusion within these segments.

Powered by Capital Market - Live News

20-Oct-2020 (17:29) Equitas Small Finance Bank IPO subscribed 39%

The initial public offer (IPO) of Equitas Small Finance Bank received bids for 4.54 crore shares on Tuesday, 20 October 2020, as against 11.58 crore shares on offer, as per the National Stock Exchange of India (NSE) website data at 17:00 IST. The issue was subscribed 0.39 times.

The issue opened for bidding today, 20 October 2020 and it will close on Thursday, 22 October 2020. The price band for the IPO was set at Rs 32-33 per share.

The IPO consists of fresh issue of shares amounting to Rs 280 crore and an offer of sale comprises of 7.20 crore shares by the bank's promoter, Equitas Holdings (including anchor portion of 4.23 crore equity shares).

Ahead of the IPO, Equitas Small Finance Bank raised Rs 139.68 crore from anchor investors on 19 October 2020. It has finalised allotment of 4,23,27,271 equity shares to anchor investors at upper price band of Rs 33 per equity share.

The bank proposes to utilize the net proceeds from the offer towards augmenting bank's Tier I capital base to meet bank's future capital requirements such as organic growth and expansion and to comply with the regulatory requirements for enhanced capital base, as may be prescribed in the future.

The listing of the bank is also in line with terms of the RBI in-principle approval, RBI final approval and SFB licensing guidelines, requiring the bank to list its equity shares on the stock exchanges within three years from the date of commencement of business by the bank.

Equitas Small Finance Bank recorded net profit of Rs 57.67 crore and total income of Rs 750.96 crore in the quarter ended on 30 June 2020.

Equitas Small Finance Bank is the largest small finance bank in India in terms of number of banking outlets and the second largest SFB in India in terms of assets under management and total deposits in FY2019. The bank has successfully diversified its loan portfolio and significantly reduced its dependence on microfinance business as compared to other microfinance companies that have converted to SFBs.

The bank offers a range of banking products and services to customers with a focus on serving the financially unserved and underserved customer segments in India. Its strength lies in promoting financial inclusion within these segments.

Powered by Capital Market - Live News

08-Oct-2020 (09:39) Likhitha Infra IPO ends with good subscription

The initial public offer (IPO) of Likhitha Infrastructure received bids for 4.84 crore shares as against 51 lakh shares on offer, as per the National Stock Exchange of India (NSE) website data. The issue was subscribed 9.51 times.

The qualified institutional buyers (QIBs) category was subscribed 21.99 times. The non-institutional investors category was subscribed 1.54 times. The retail individual investors (RIIs) category was subscribed 23.71 times.

The issue opened for bidding on 29 September 2020. It was set to close on 1 October 2020. However, due to weak participation from the qualified institutional buyers (QIBs), the IPO was extended till 7 October 2020. The company also revised its price band to Rs 116-120 from Rs 117-120 set earlier.

The public issue comprised a fresh issue of 51 lakh equity shares, representing 25.86% of post issue paid up equity. The company proposes to utilize the IPO proceeds towards meeting the working capital requirements (Rs 47 crore), general corporate purposes and issue expenses.

The company recorded sales of Rs 161.24 crore and profit after tax of Rs 19.88 crore in the year ended on 31 March 2020.

Likhitha Infrastructure (LIL) is an oil & gas pipeline infrastructure service provider in India. Its operations include three principal business lines: (i) cross country pipelines and associated facilities; (ii) city gas distribution including CNG stations; and (iii) operation & maintenance of CNG/PNG services.

Powered by Capital Market - Live News

  • showing 1 to 10 of 100 entries
  • Show
  • entries
 PREVIOUS 123 NEXT